Adverse Events Associated With Bevacizumab and Chemotherapy in Older Patients With Metastatic Colorectal Cancer

Micro-Abstract The safety of bevacizumab in older metastatic colorectal cancer (mCRC) patients is not well characterized. A total of 6821 mCRC patients age ≥ 65 were identified from Surveillance, Epidemiology and End Results Program (SEER)-Medicare and were categorized by first-line treatment (none,...

Full description

Saved in:
Bibliographic Details
Published in:Clinical colorectal cancer 2013-09, Vol.12 (3), p.204-213.e1
Main Authors: Shankaran, Veena, Mummy, David, Koepl, Lisel, Blough, David, Yim, Yeun Mi, Yu, Elaine, Ramsey, Scott
Format: Article
Language:English
Subjects:
Adenocarcinoma - complications
Adenocarcinoma - drug therapy
Adenocarcinoma - secondary
Aged
Antibodies, Monoclonal, Humanized - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Bevacizumab
Camptothecin - administration & dosage
Camptothecin - analogs & derivatives
Capecitabine
Colorectal Neoplasms - complications
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - pathology
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Drug-Related Side Effects and Adverse Reactions - diagnosis
Drug-Related Side Effects and Adverse Reactions - epidemiology
Drug-Related Side Effects and Adverse Reactions - etiology
Female
First-line
Fluorouracil - administration & dosage
Fluorouracil - analogs & derivatives
Follow-Up Studies
Gastroenterology and Hepatology
Hematology, Oncology and Palliative Medicine
Humans
Incidence
Incidence of adverse events
Male
Neoplasm Staging
Organoplatinum Compounds - administration & dosage
Preexisting conditions
Prognosis
Safety
SEER Program
SEER–Medicare
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract The safety of bevacizumab in older metastatic colorectal cancer (mCRC) patients is not well characterized. A total of 6821 mCRC patients age ≥ 65 were identified from Surveillance, Epidemiology and End Results Program (SEER)-Medicare and were categorized by first-line treatment (none, chemotherapy alone, chemotherapy and bevacizumab). First-line bevacizumab was not associated with increased adverse event (AE) incidence or first AE risk compared with chemotherapy alone, when controlling for potential confounders.
ISSN:1533-0028
1938-0674
DOI:10.1016/j.clcc.2012.11.004